The application value of Metoprolol combined with Dagalizin in enhancing cardiac function and ventricular remodeling in patients with acute myocardial infarction after PCI.

 The application value of Metoprolol combined with Dagalizin in enhancing cardiac function and ventricular remodeling in patients with acute myocardial infarction after percutaneous coronary intervention. J Clin Emerg, 2024, 25(4): 170-174. doi: 10.13201/j.issn.1009-5918.2024.04.003 Abstract To discuss the application value of metoprolol combined with daglizin in improving cardiac function and ventricular remodeling in patients with acute myocardial infarction(AMI) after percutaneous coronary intervention(PCI).  A total of 86 patients with acute myocardial infarction I- percutaneous coronary intervention from January 2022 to October 2023 were selected and divided into experimental group(43 cases) and control group(43 cases) according to a random table. Patients in the control group were given metoprolol + conventional treatment and patients in the experimental group were given combined treatment with daglizin on this basis. The cardiac function(left ejection fraction[LVEF], heart index[CI], stroke output[SV]), ventricular remodeling(left ventricular end-diastolic volume[LVEDV], left ventricular end-systolic volume[LVESV], left ventricular end-diastolic diameter[LVEDD]) and laboratory parameters(N-terminal B-type natriuretic peptide precursor[NT-proBNP], hypersensitive C-reactive protein[hs-CRP], interleukin-6[IL-6]), adverse cardiovascular events and adverse events were compared between the two groups.  After treatment, the left ejection fraction, heart index and stroke output of the two groups were significantly higher than those before treatment, and the left ejection fraction, heart index and stroke output in the experimental group were significantly higher than those in the control group(P < 0.05). After treatment, the Left ventricular end-diastolic volume, left ventricular end-systolic volume, left ventricular end-diastolic diameter, N-terminal B-type natriuretic peptide precursor, hypersensitive C-reactive protein and  interleukin-6of the two groups were significantly lower than those before treatment, and Left ventricular end-diastolic volume, left ventricular end-systolic volume, left ventricular end-diastolic diameter, N-terminal B-type natriuretic peptide precursor, hypersensitive C-reactive  protein and interleukin-6in the experimental group were significantly lower than those in the control group(P < 0.05). The incidence of adverse cardiovascular events in the experimental group was significantly lower than that in the control group(P < 0.05). The adverse events rate of the two groups was basically the same(P>0.05).  Metoprolol combined with daglizin can improve cardiac function and ventricular remodeling in patients with acute myocardial infarction (AMI) after percutaneous coronary intervention(PCI), which is beneficial for prognosis improvement, and it is worthy of clinical promotion.   Disclaimer: Lupin makes no representation or warranty of any kind, expressed or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any scientific information shared by the HCP on the ­­­STAR UPDATE podcast. You should not allow the contents of this to substitute for your own medical judgment, which you should exercise in evaluating the information on this website